A Foreword from the Editor
Vol 1, Issue 1, 2016, Article identifier:1-2
VIEWS - 445 (Abstract) 267 (PDF)
Abstract
Full Text:
PDFReferences
Chesbrough H W, 2003, Open Innovation: The new im-perative for creating and profiting from technology. Harvard Business School Press, Boston
AB InBev open innovation submission portal n.d., viewed April 8, 2015,
Crowed revved up by BMW open innovation contest n.d., viewed April 8, 2015,
Khanna I, 2012, Drug discovery in pharmaceutical in-dustry: productivity challenges and trends. Drug Dis-covery Today, vol.17(19–20): 1088–1102. http://dx.doi.org/10.1016/j.drudis.2012.05.007.
Schuhmacher A, Germann P G, Gassmann O, et al. 2013, Models for open innovation in the pharmaceutical in-dustry. Drug Discovery Today, vol.18(23–24): 1133– 1137. http://dx.doi.org/10.1016/j.drudis.2013.07.013.
Bianchi M, Cavaliere A, Chiaroni D, et al. 2011, Organisational modes for open innovation in the bio-pharma-ceutical industry: an exploratory analysis. Technovation, vol31: 22–33. http://dx.doi.org/10.1016/j.technovation.2010.03.002.
Dahlem A M, 2012, Open innovation, networks, and strategic partnerships in drug discovery and develop-ment n.d., viewed April 10, 2015,
Open innovation drug discovery n.d., viewed April 8, 2015
Open innovation n.d., viewed April 10, 2015,
Centers for therapeutic innovation n.d., viewed April 11, 2015,
GSK consumer healthcare open innovation n.d., viewed April 11, 2015,
Innovative medicines initiative n.d., viewed April 10, 2015,
Critical path institute n.d., viewed April 15, 2015,
TransCelerate BioPharma n.d., viewed April 16, 2015,
DOI: http://dx.doi.org/10.18063/jmds.v1i1.112
(445 Abstract Views, 267 PDF Downloads)
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Jean-Marie Boeynaems

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.